PURPOSE OF REVIEW: This article reviews the evidence base for the preventive treatment of migraine. RECENT FINDINGS: Evidence-based guidelines for the preventive treatment of migraine have recently been published by the American Academy of Neurology (AAN) and the Canadian Headache Society (CHS), providing valuable guidance for clinicians. Strong evidence exists to support the use of metoprolol, timolol, propranolol, divalproex sodium, sodium valproate, and topiramate for migraine prevention, according to the AAN. Based on best available evidence, adverse event profile, and expert consensus, topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, Petasites (butterbur), riboflavin, coenzyme Q10, and magnesium citrate received a strong recommendation for use from the CHS. SUMMARY: Migraine preventive drug treatments are underutilized in clinical practice. Principles of preventive treatment are important to improve compliance, minimize side effects, and improve patient outcomes. Choice of preventive treatment of migraine should be based on the presence of comorbid and coexistent illness, patient preference, reproductive potential and planning, and best available evidence.
PURPOSE OF REVIEW: This article reviews the evidence base for the preventive treatment of migraine. RECENT FINDINGS: Evidence-based guidelines for the preventive treatment of migraine have recently been published by the American Academy of Neurology (AAN) and the Canadian Headache Society (CHS), providing valuable guidance for clinicians. Strong evidence exists to support the use of metoprolol, timolol, propranolol, divalproex sodium, sodium valproate, and topiramate for migraine prevention, according to the AAN. Based on best available evidence, adverse event profile, and expert consensus, topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, Petasites (butterbur), riboflavin, coenzyme Q10, and magnesium citrate received a strong recommendation for use from the CHS. SUMMARY:Migraine preventive drug treatments are underutilized in clinical practice. Principles of preventive treatment are important to improve compliance, minimize side effects, and improve patient outcomes. Choice of preventive treatment of migraine should be based on the presence of comorbid and coexistent illness, patient preference, reproductive potential and planning, and best available evidence.
Authors: Tamara Pringsheim; W Jeptha Davenport; Gordon Mackie; Irene Worthington; Michel Aubé; Suzanne N Christie; Jonathan Gladstone; Werner J Becker Journal: Can J Neurol Sci Date: 2012-03 Impact factor: 2.104
Authors: R O Millán-Guerrero; R Isais-Millán; S Barreto-Vizcaíno; I Gutiérrez; L Rivera-Castaño; B Trujillo-Hernández; L M Baltazar Journal: Eur Neurol Date: 2008-02-08 Impact factor: 1.710
Authors: Carlos A Bordini; Hilton Mariano da Silva; Roberta P Garbelini; Simone O Teixeira; José G Speciali Journal: J Headache Pain Date: 2005-08-01 Impact factor: 7.277
Authors: Paul K Winner; Peter McAllister; George Chakhava; Jessica Ailani; Anders Ettrup; Mette Krog Josiassen; Annika Lindsten; Lahar Mehta; Roger Cady Journal: JAMA Date: 2021-06-15 Impact factor: 56.272
Authors: Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi Journal: Front Pharmacol Date: 2021-05-21 Impact factor: 5.810